Salestools LogoSalestools
Agentes IA de Salestools
Soluciones
Recursos
Empresa
Precios
Salestools Logo

Salestools

El agente IA #1 para equipos de ventas y Go-to-Market. Vende más, más rápido, con menos esfuerzo.

Producto

  • Agentes de ventas IA
  • Datos de intención
  • Datos tecnológicos
  • Seguimiento de visitantes
  • Co-Pilot
  • Venta social

Soluciones

  • Servicio al cliente
  • Comercio electrónico
  • SaaS
  • Empresarial
  • Pequeña empresa

Recursos

  • El informe
  • Documentación
  • Referencia de API
  • Centro de ayuda
  • Blog
  • Casos de estudio
  • Webinars

Empresa

  • Acerca de
  • Carreras
  • Prensa
  • Contacto
  • Socios

Nuestras ubicaciones

  • Nueva York, HQ
  • Bucarest, laboratorio de investigación IA
  • Zug, Suiza

© 2026 Salestools. Todos los derechos reservados.

Términos de datos y seguridadPolítica de privacidadTérminos de servicioAcceptable Use
Todos los sistemas operativos
Salestools LogoSalestools
Agentes IA de Salestools
Soluciones
Recursos
Empresa
Precios
Back to Reports
Fundraising

Lumeris

Lumeris Raises $100M in Growth

St. Louis, MOApril 30, 20242 min read
Employees
500+

Lumeris Raises $100M in Growth


Lumeris has successfully raised $100M in a Growth at a $600M valuation led by Centene Corporation, Clayton Dubilier & Rice.


Company Overview


Lumeris is a HealthTech company headquartered in St. Louis, MO, founded in 2012 with 500+ employees.


Healthcare spending and value-based care platform


Fundraising Details


  • Amount Raised: $100M
  • Round Type: Growth
  • Valuation: $600M
  • Date: 2024-04-30
  • Investors: Centene Corporation, Clayton Dubilier & Rice

About Lumeris


Healthcare spending and value-based care platform The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: St. Louis, MO
  • Founded: 2012
  • Team Size: 500+
  • Industry: HealthTech

What This Means


This funding round demonstrates strong investor confidence in Lumeris's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Lumeris's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $600M valuation marks an important milestone for Lumeris, positioning the company among notable players in the HealthTech industry.


Looking Ahead


With this new capital, Lumeris is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-04-30. For more information about Lumeris, visit their headquarters at St. Louis, MO.

Company Info

Headquarters
St. Louis, MO
Founded
2012
Team Size
500+

Topics

Fundraising(2912)HealthTech(503)GrowthLumeris

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free